Search results
Results from the WOW.Com Content Network
The RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) was a multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erdosteine 300 mg/bid added to usual maintenance therapy vs. placebo over 12-months, a period long enough to avoid bias due to seasonal ...
Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in very similar pharmacological effects. [6] Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach. [citation needed]
Nembutal capsule. Abbott discontinued its Nembutal brand of pentobarbital capsules in 1999, largely replaced by the benzodiazepine family of drugs. Abbott's Nembutal, known on the streets as "yellow jackets", was widely abused. [33] [34] They were available as 30, 50, and 100 mg capsules of yellow, white-orange, and yellow colors, respectively ...
Different sources note different incidence of side effects. The most common side effect is breakthrough bleeding. Combined oral contraceptive pills can improve conditions such as dysmenorrhea, premenstrual syndrome, and acne, [105] reduce symptoms of endometriosis and polycystic ovary syndrome, and decrease the risk of anemia. [106]
CPA/EE-containing birth control pills were developed by 1975 [20] [21] and were first introduced for medical use in 1978. [22] They originally contained 50 μg EE (Diane); subsequently, the EE dosage was decreased to 35 μg in a new "low-dose" preparation in 1986 (Diane-35).
In the amycretin trial, the side effects were related to gastrointestinal discomfort, including nausea and vomiting, similar to those seen in trials of its other medicines from the same GLP-1 drug ...
The pharmacokinetics of dienogest are linear; single oral doses of dienogest were found to result in maximal levels of 28 ng/mL with 1 mg, 54 ng/mL with 2 mg, 101 ng/mL with 4 mg, and 212 ng/mL with 8 mg. [7] The corresponding area-under-the-curve levels were 306, 577, 1153, and 2293 ng/mL, respectively. [7]
Side effects of droxidopa include headache, dizziness, nausea, and hypertension, among others. [2] Droxidopa is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine (noradrenaline). [4] Hence, it acts as a non-selective agonist of the α-and β-adrenergic receptors.